Pure Global
NCT06297863

Head Down Tilt 15° to Increase Collateral Flow in Acute Ischemic Stroke

Head Down Tilt 15° to Increase Collateral Flow in Acute Ischemic Stroke: a Multicenter, Randomised, Proof of Concept, Phase 2a/b Trial in Patients Treated With Mechanical Thrombectomy
University of Milano Bicocca·Phase 2·ClinicalTrials.gov·procedureNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Ischemic Stroke
Drug/Device/Intervention
HEAD DOWN TILT -10° to -15°
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
University of Milano Bicocca
Timeline & enrollment
Phase
Phase 2
Start date
Oct 01, 2024
End date
Dec 31, 2026
Enrollment
118 participants
Primary outcome

Good collateral status

Summary

The DOWN-SUITE study is multicenter, randomised, controlled, open-label clinical trial with
 blinded outcome assessment comparing collateral status in patients with acute ischemic stroke
 treated with an in-hospital application of head down tilt -10° to -15° (HDT15) versus usual
 positioning (0° to +30°) before endovascular mechanical thrombectomy.
 
 This study will involve adult patients who are eligible for mechanical thrombectomy and who
 have acute ischemic stroke due to left or right middle cerebral artery occlusion (M1
 segment).
 
 The investigators hypothesise that HDT15, applied in acute ischemic stroke patients with a
 large vessel occlusion, will improve collateral circulation, prolong the survival of the
 ischemic penumbra and improve the clinical benefit from mechanical thrombectomy compared with
 standard of care (usual positioning 0° to +30°).

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedTransient cerebral ischaemic attack, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06297863
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06297863 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Milano Bicocca and is currently Not yet recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 118 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.